Immunovant, Inc. $IMVT Shares Acquired by Granahan Investment Management LLC

Posted by Francis Steltz on Jul 25th, 2026

Granahan Investment Management LLC lifted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 244,430 shares of the company’s stock after purchasing an additional 14,242 shares during the period. Granahan Investment Management LLC owned about 0.12% of Immunovant worth $6,072,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Deep Track Capital LP raised its stake in Immunovant by 2.4% in the third quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock valued at $156,829,000 after buying an additional 228,845 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Immunovant by 14.0% during the 4th quarter. Vanguard Group Inc. now owns 7,779,314 shares of the company’s stock worth $197,750,000 after acquiring an additional 952,504 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Immunovant by 12.2% in the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $94,076,000 after acquiring an additional 636,000 shares during the last quarter. Morgan Stanley increased its holdings in shares of Immunovant by 147.4% in the 4th quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock valued at $123,195,000 after acquiring an additional 2,887,359 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Immunovant by 30.9% in the 4th quarter. State Street Corp now owns 3,786,926 shares of the company’s stock valued at $96,264,000 after acquiring an additional 894,308 shares during the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Insider Activity

In other Immunovant news, CTO Jay S. Stout sold 40,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $38.31, for a total value of $1,532,400.00. Following the transaction, the chief technology officer directly owned 211,685 shares of the company’s stock, valued at approximately $8,109,652.35. The trade was a 15.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Melanie Gloria sold 17,714 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $38.31, for a total transaction of $678,623.34. Following the transaction, the chief operating officer owned 224,393 shares of the company’s stock, valued at approximately $8,596,495.83. The trade was a 7.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 327,312 shares of company stock valued at $11,418,145. Insiders own 1.80% of the company’s stock.

Immunovant Trading Up 0.1%

IMVT stock opened at $39.41 on Friday. The company has a market capitalization of $8.09 billion, a P/E ratio of -14.18 and a beta of 0.76. Immunovant, Inc. has a twelve month low of $14.32 and a twelve month high of $41.23. The business has a 50 day simple moving average of $35.87 and a 200-day simple moving average of $29.67.

Immunovant (NASDAQ:IMVT – Get Free Report) last announced its earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same quarter last year, the business earned ($0.64) EPS. Research analysts predict that Immunovant, Inc. will post -2.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on IMVT shares. Guggenheim boosted their target price on Immunovant from $44.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Truist Financial increased their price target on shares of Immunovant from $23.00 to $30.00 and gave the company a “hold” rating in a research note on Friday, May 22nd. Citigroup raised their price objective on shares of Immunovant from $57.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. HC Wainwright boosted their price objective on shares of Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Finally, The Goldman Sachs Group upped their target price on shares of Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $39.70.

View Our Latest Analysis on IMVT

About Immunovant

(Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.